Ankur Varma

Associate Professor

Last publication 2026 Last refreshed 2026-05-16

faculty

COM | Internal Med Hem-Onc

14 h-index 88 pubs 928 cited

Biography and Research Information

OverviewAI-generated summary

Ankur Varma researches hematopoietic stem cell transplantation, with a focus on treatment outcomes and associated complications. His work has investigated factors influencing outcomes in patients undergoing allogeneic stem cell transplants, including the role of donor-specific anti-HLA antibodies and the impact of myeloablative total body irradiation on graft-versus-host disease. Varma has also explored specific complications such as hyperhemolysis in sickle cell disease and Human herpesvirus 6-associated hyponatremia. His research includes clinical trials, such as a Phase 1 study of briquilimab in combination with conditioning regimens for acute myeloid leukemia and myelodysplastic syndrome. Varma's publications also address myeloproliferative neoplasms in blast phase and emerging syndromes like immune effector cell-associated HLH-like syndrome. He has an h-index of 14 and has authored 86 publications.

Metrics

  • h-index: 14
  • Publications: 88
  • Citations: 928

Selected Publications

  • Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS (2026)
  • Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)
  • Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)
  • Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)
  • Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)
  • Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)
    4 citations DOI OpenAlex
  • The Effect of Sickle Cell Disease on Seizure-Related Hospitalizations: An Analysis of the Nationwide Inpatient Sample 2021 (2025)
  • Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)
  • Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)
    3 citations DOI OpenAlex
  • Simultaneous Presentation of Relapsed Diffuse Large B-cell Lymphoma and Extrapulmonary Tuberculosis in a Patient With HIV: A Case Report (2025)
  • Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting (2024)
  • Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)
  • Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy (2024)
  • Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021) (2024)
  • Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)

View all publications on OpenAlex →

Grants & Funding

  • MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group Principal Investigator
  • MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group Principal Investigator

Collaboration Network

157 Collaborators 28 Institutions 5 Countries

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics